SlideShare a Scribd company logo
Home nebulisation
Dr. Aditya Jindal
Interventional Pulmonologist & Intensivist
Jindal Clinics
SCO 21, Sec 20D, Chandigarh
DM Pulmonary and Critical Care Medicine (PGI Chandigarh),
FCCP
The respiratory tract has evolved to keep inhaled particles
out of the lungs, and to remove or inactivate them once
deposited ...
The adult lung
with dimensions
and generations
of the airways
with predicted
aerosol
deposition
Roy pleasants et al. Respiratory care. 2018
Newman S P.Ther. Deliv. (2017)
Factors influencing optimal delivery of inhaled
drugs
Droplet size
Impaction
Diffusion
Sedimentation
Pattern of
inhalation
Speed
Cognition, disease
severity, and
clinical status of
patient
Roy pleasants et al. Respiratory care. 2018
Particles <5 µm  peripheral airways
Particle > 5 µm  central airways
Newman S P.Ther. Deliv. (2017)
Inhaler devices
• Widespread hand-held inhalers’ devices are
represented by
• Dry powder inhalers (DPIs)
• Pressurized metered dose inhalers (pMDIs)
• Soft mist inhalers (SMIs)
• Nebulizers are often left for the treatment of acute
conditions such as COPD exacerbations or in
patients with extremely limited self-sufficiency.
Inhaler devices??
Dolovich MB, Ahrens RC, Hess DR, et al. Chest. 2005;127(1):335–371.
Advantages and disadvantages of different types of inhaler devices in
asthma and COPD
Inhaler Formulation Metering system Pros Cons
pMDI
Drug suspended or dissolved
in propellant (With surfactant
or cosolvent)
Metering valve and
reservoir
Compact and portable.
Can be used independently.
Dose counters
Slow inhalation can be achieved
Not breath actuated
Not good for elderly
Cold Freon effect
Coordination issues
Adding spacer makes it cumbersome and
costly
MDI with spacer
Drug suspended or dissolved
in propellant (With surfactant
or cosolvent)
Metering valve and
reservoir
Easy to coordinate
Decreases oropharyngeal deposition
Eliminates Cold Freon effect
DPI
Drug blend in lactose or drug
alone/drug excipient
particles/multidose blister
reservoirs
Capsules/blisters/
Compact and portable
Do not require coordination
Doesn’t contain propellants
Requires minimum inspiratory flow
Cant be used in emergencies
Difficult in patients with cognitive
impairment and elderly
Most are moisture sensitive
SMI
Aqueous solution or
suspension
Unit dose blisters or
reservoirs
Compact and portable
Doesn’t contain propellants
Smaller dose of bronchodilator is
required
Metered volume of 15 mcl limits the
dose deliver capacity
Paola Rogliani et al. Respiratory Medicine 124 (2017) 6e14
Device errors in asthma and COPD:
Meta analysis
• Studies in adult males and females with asthma or COPD,
reporting at least one overall or critical error, using metered
dose inhalers and dry powder inhalers were included.
• Random-effect metaanalyses were performed to estimate
device error rates and to compare pairs of devices.
H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
Meta-analysis of the overall error rate frequency for pMDI in prospective/cross-sectional studies
Summary results for the MDI devices estimated an overall
error frequency of 86.8% [95% CI 79.4–91.9] of patients with
at least one error
H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
Meta-analysis of the overall error rate frequency (a) for DPIs in prospective/cross-sectional
studies
H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
Device errors
in asthma and
COPD:
Metaanalysis
H.Chrstyn et al.npj Primary Care Respiratory
Medicine (2017) 27:22
14 Factors Influencing Device Prescription
Cleve Clin J Med. 2018 Feb;85(2 Suppl 1):S19-S27
J Assoc Physicians India. 2017 May;65(5):60-73
Chronic Obstr Pulm Dis. 2018; 5(2): 111–123.
1. Cognition
2. Manual dexterity
3. Comorbidities
4. Preference and
outlook
5. Age
6. Poor eyesight
Patient related
1.Type of drugs
2. Combination
3. Frequency of
dosing
4. Strength of dose
5. Side effects
6. Large doses (if
required)
Drug related
1. Severity of disease
2. Respiratory status-
lung condition
Disease related
Device related
1.Ease of use
2. Device efficacy
3. Cost
4. Duration of use
Selecting Inhalation Device should be Based on
Quality Of Actuation-inhalation Coordination & PIFR
ERS Annual Congress London 2016
15
It is also recommended that patient preferences for devices should be
considered when prescribing an inhaler, but physicians must be cognizant
that patients often overestimate their ability to handle a device correctly
16
Ann Am Thorac Soc. 2017 Aug;14(8):1305-1311
1. sPIF is common during AECOPD and predicts all-cause and COPD readmission. Patients with sPIF
may benefit therapies.
2. We recommend checking PIF in patients hospitalized for AECOPD for selection of delivery devices
1. Suboptimal PIFR (<60 L/min) has been observed in 19%-78% of stable outpatients and 32%–52% of
inpatients before discharge from the hospital after treatment for COPD exacerbation
2. Patients with COPD and sPIFR had more severe dyspnea than patients with similar
obstruction and optimal PIFR
https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1132
17
Benefit of nebulization in patients with sub-optimal PIFR
Ann Am Thorac Soc. 2017;14:1305–1311; J COPD Found. 2017;4:217–224.
• Patients with suboptimal PIFR (<60L/min) discharged with nebulizers had significantly
lower rates of COPD readmission as compared with those discharged on DPIs.
Hospital Readmission
70
50
17
10 20 30 40 50 60 70 80 90 100
% of COPD-readmission < 90 D
% of COPD-readmission < 30 D
Nebulizer DPI
(N=12) (N=10)
P<0.005
P<0.011
• Drug delivery via nebulization:
• An effective alternative
• An optimal dose can be delivered during tidal
breathing.
• Can be used with diferent disease severity or
associated comorbidities,
• Overcomes the need for coordination, specific
handling and inspiratory maneuvers
Nebulized devices??
Pierachille Santus, Dejan Radovanovic, Andrea Cristiano et al.2017:11 3257–3271
Types of
Nebulizers
Alok G.Ghosal et al. Journal of The Association of Physicians of India.2017;65:60-73
L. Vecellio. Breathe Mar 2006
Jet nebuliser
L. Vecellio. Breathe Mar 2006
Ultrasonic nebuliser
L. Vecellio. Breathe Mar 2006
Mesh nebuliser
Patient profile for Nebulization
• Patients with severe disease and exacerbations
• During exacerbations where higher doses are needed
• Elderly patients>60 years
• Patients with physical and cognitive limitations
• Patient preference
Eur Respir J 2001; 18: 228–242
Ann Transl Med 2019;7(18):487
What guidelines say about
nebulization?
GOLD 2020
GOLD guidelines 2020
Algorithm to identify
OAD patients for
maintenance
nebulization
*Clinical improvement should be assessed as
recommended by the respective treatment
guidelines.
#Device technique should be assessed as per the
patient information literature provided with the
device.
+Unsatisfactory device technique is any deviation
from the recommended device technique described
in the patient information literature provided with
the device
Alok G.Ghosal et al. Journal of The Association of
Physicians of India.2017;65:60-73
Indian consensus
statement on
maintenance
nebulization
Guidelines
in snapshot
Cassandra D. Benge and John Alan Barwise. Federal practitioner (2020),160-163
Drugs available
in India for
maintenance
Nebulization
Ghoshal AG, Salvi S, Dhar R, et al. J Assoc Physicians India. 2017;65(5):60-73.
Nebulization in COVID 19 pandemic
COVID 19 transmission
• Spread by droplets generated as bioaerosols.
• Aerosol transmission of SARS-CoV-2 is now considered to be
the main method of transmission because the virus can remain
viable and infectious in aerosols for hours
Ari A. Respir Med. 2020;167:105987.
Fugitive emissions during nebulization
Fugitive emission is defined
as aerosols that have been
released from the aerosol
device during patient
expiration.
It is also medical aerosols
that are not inhaled by the
patient but passes into the
atmosphere.
Previous studies: the
particle size ranges from
0.860 to 1.437 μm
Up to 50% of the generated
aerosol during therapy was
fugitive aerosol remain
airborne in the indoor
environment for several
hours .
Factors affecting fugitive emissions: The device,
interface, patient type, and flow rate of nebulizer,
dimensions and layout of the room, air turbulence,
airflow rates, and temperature impact dispersion and
decay
Ari A. Respir Med. 2020;167:105987.
Respir Care 2015
Advise patients to have their full supply of
medication at home1
Perform nebulization in a well ventilated room
Prevent your caretaker/family member from
staying inside the room during nebulization
DON’T let the caretaker get too close while
Nebulization is being conducted. Maintain
distance of at least 6 feet from the patient.
Close the door while nebulization is being
undertaken.2
DON’T share nebulizers between
family members. Every nebulizer
should be a single-use nebulizer2.
Avoid air-conditioning in the room
altogether5.
DO leave the room vacant with the
door closed for 30 minutes after the
patient has vacated the room post-
nebulization.4
Wash the accessories as per the guide
and use disinfectants like Isopropanol
(70%) or Hydrogen Peroxide (3%) 4.
1WHO Interim guidelines 2019; 2CDC guidelines www.health.state.mn.us; 3https://www.cdc.gov/coronavirus/2019-ncov/hcp/hand-hygiene.html;
4https://www.health.qld.gov.au/data/assets/pdf_file/0038/939656/qh-covid-19-Infection-control-guidelines.pdf; 5www.ncdc.gov
Good Nebulization Practice at HOME Setting
Advantages of Nebulization
J Assoc Physicians India. 2017 May;65(5):60-73; Nurse Prescribing. 2016 Dec 2;14(12):586-92
Med Devices (Auckl). 2015 Feb 12;8:131-9; Clinical Pediatrics;Vol. 47 No. 8; 2008
1. No patient coordination required.
2. Efficient delivery possible in patients with low
inspiratory flow rate
3. Breath holding not required
4. Large doses can be administered
• Issues with nebulisation
• Droplet size formed is not uniform; may vary over 10 fold
• Dose delivery depends on
• Initial volume fill
• Efficiency of aerosolisation of medicine
• Amount residual/dead volume (0.5 – 1.5 ml)
• Breath actuation vs continuous use
Newman S P.Ther. Deliv. (2017)
Alhaddad B et al. BMJ Open Resp Res 2015
Alhaddad B et al. BMJ Open Resp Res 2015
Cochrane Review: Nebulizers vs pMDI vs DPI
• There is a lack of evidence in favour of one mode of delivery over
another for bronchodilators during exacerbations of COPD.
• No difference between nebulisers versus pMDI plus spacer regarding
the primary outcomes of FEV1 at one hour and safety.
• Secondary outcome: Change in FEV1 closest to one hour after dosing'
during an exacerbation of COPD, a greater improvement in FEV1
when treating with nebulisers than with pMDI plus spacers.
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database of Systematic Reviews 2016, Issue 8. Art.
No.: CD011826.
Summary
• Inhalation therapy is the preferred route of drug administration for treating COPD.
• In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers
requires less intensive patient training.
• However, home nebulisation has its own problems and issues
• If nebulized medications need to be used in patients with COVID-19 adequate precautions should be taken
Home nebulisation

More Related Content

PPTX
2D ECHO in pulmonology
PPTX
Broncho provocation testing ppt
PPTX
Bronchiectasis
PPT
PDF
Progressive Fibrosing Interstitial Lung Disease: Shining a Light on the Lates...
PPTX
Ards m ibrahim
PPTX
Idiopathic interstitial pneumonias
PPTX
Lung volume reduction surgery ( LVRS )
2D ECHO in pulmonology
Broncho provocation testing ppt
Bronchiectasis
Progressive Fibrosing Interstitial Lung Disease: Shining a Light on the Lates...
Ards m ibrahim
Idiopathic interstitial pneumonias
Lung volume reduction surgery ( LVRS )

What's hot (20)

PPTX
Lung Volume Reduction Surgery
PPTX
Asthma-COPD Overlap Syndrome(ACOS)- an update
PPT
Bronchial Asthma- Recent advances in management by Dr. Jebin Abraham
PPT
Electromagnetic Navigation Bronchoscopy (ENB): Clinical Review
PPSX
Icu management in obstructive airway disease
PPTX
Lung volume reduction surgery
PPTX
Hemoptysis , definition, classification, causes and management
PPSX
Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome
PPTX
Steroid resistent asthma
PPSX
Copd indacaterol trials
PPTX
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe Asthma
PPT
Inda glyco
PPTX
Approach To Interstitial Lung Diseases
PPTX
Steroid Resistant Asthma | Jindal Chest Clinic
PPTX
Progressive Pulmonary Fibrosis definition & management
PPTX
IPF AND PROGRESSIVE PULMONARY FIBROSIS 2022UPDATE(ATS.pptx
PPTX
Riociguat for the treatment of pah
PPTX
Body plethesmography
Lung Volume Reduction Surgery
Asthma-COPD Overlap Syndrome(ACOS)- an update
Bronchial Asthma- Recent advances in management by Dr. Jebin Abraham
Electromagnetic Navigation Bronchoscopy (ENB): Clinical Review
Icu management in obstructive airway disease
Lung volume reduction surgery
Hemoptysis , definition, classification, causes and management
Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome
Steroid resistent asthma
Copd indacaterol trials
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe Asthma
Inda glyco
Approach To Interstitial Lung Diseases
Steroid Resistant Asthma | Jindal Chest Clinic
Progressive Pulmonary Fibrosis definition & management
IPF AND PROGRESSIVE PULMONARY FIBROSIS 2022UPDATE(ATS.pptx
Riociguat for the treatment of pah
Body plethesmography
Ad

Similar to Home nebulisation (20)

PPTX
Nebulisation therapy in COVID 19 era.pptx
PDF
aerosol_handout
PDF
Aerosol therapy
PPTX
Gnp and home nebulization
PPTX
Asthma Inhaler Techniques In Children
PPT
Aerosol therapy
PPT
recent advance aerosol by chetan
PPTX
Demystifying Nebulization | Jindal Chest Clinic
PPTX
Smart Inhaler "Time to Get Smarter"
PPTX
Inhaled Medications Used in Respiratory Disease
PPTX
Asthma and inhaler usage tips - part 1
PPTX
inhalers-and-the-environment-for-a-greener-nhs.pptx
PDF
Inhaler Standards MASTER 6TH12
PPTX
Grey Black White All-Purpose Minimalist Template.pptx
PPTX
Respiratory devices 4 december 2018(21 nov)
PDF
Principles for nebulization
 
DOC
OSCE inhaler and nebuliser protocol
PPTX
eRTD PPT on .......Home Nebulization.pptx
PPTX
Asthma devices.pptx
PPTX
Pulmonary
Nebulisation therapy in COVID 19 era.pptx
aerosol_handout
Aerosol therapy
Gnp and home nebulization
Asthma Inhaler Techniques In Children
Aerosol therapy
recent advance aerosol by chetan
Demystifying Nebulization | Jindal Chest Clinic
Smart Inhaler "Time to Get Smarter"
Inhaled Medications Used in Respiratory Disease
Asthma and inhaler usage tips - part 1
inhalers-and-the-environment-for-a-greener-nhs.pptx
Inhaler Standards MASTER 6TH12
Grey Black White All-Purpose Minimalist Template.pptx
Respiratory devices 4 december 2018(21 nov)
Principles for nebulization
 
OSCE inhaler and nebuliser protocol
eRTD PPT on .......Home Nebulization.pptx
Asthma devices.pptx
Pulmonary
Ad

More from Jindal Chest Clinic (20)

PPT
Medical Thoracoscopy | Jindal Chest Clinic
PPTX
Challenges in expanding lung transplantation in India | Jindal Chest Clinic
PPTX
Trans-bronchial needle aspiration | Jindal Chest Clinic
PPT
MEDICAL INFORMATICS | Jindal chest clinic
PPT
Newer Trends in Sepsis and Septic Shock |
PPT
HIV-TB Coinfection | Jindal chest clinic
PPT
TB Huminis et bovis | Jindal Chest Clinic
PPT
Health Vs Disease | Jindal Chest Clinics
PPTX
Evidence based management of community acquired Pneumonias | Jindal Chest Clinic
PPT
Diagnosing Pulmonary Infections in the ICU | Jindal Chest Clinic
PPT
Ethics in Medicine | Jindal Chest clinic
PPTX
Good Clinical Practices | JindalChest Clinic
PPTX
EFFECT OF MAGNESIUM SULPHATE IN THE TREATMENT OF ASTHMA.pptx
PPT
End of life care in the elderly | Jindal Clinics by Dr. S.K Jindal
PPT
Medico-Legal Issues | Jindal Chest Clinic
PPT
Optimizing Management of asthma and COPD.ppt
PPTX
Role of Allergen Immunotherapy in Allergic Asthma | Jindal Chest Clinic Chand...
PPT
Non-Respiratory Functions of The Respiratory System | Jindal Chest Clinic
PPT
Short Acting Beta-2 Agonists (SABA) in Asthma | Jindal Chest Clinic Chandigarh
PPT
Presentation on "Allergy" | Jindal chest clinic
Medical Thoracoscopy | Jindal Chest Clinic
Challenges in expanding lung transplantation in India | Jindal Chest Clinic
Trans-bronchial needle aspiration | Jindal Chest Clinic
MEDICAL INFORMATICS | Jindal chest clinic
Newer Trends in Sepsis and Septic Shock |
HIV-TB Coinfection | Jindal chest clinic
TB Huminis et bovis | Jindal Chest Clinic
Health Vs Disease | Jindal Chest Clinics
Evidence based management of community acquired Pneumonias | Jindal Chest Clinic
Diagnosing Pulmonary Infections in the ICU | Jindal Chest Clinic
Ethics in Medicine | Jindal Chest clinic
Good Clinical Practices | JindalChest Clinic
EFFECT OF MAGNESIUM SULPHATE IN THE TREATMENT OF ASTHMA.pptx
End of life care in the elderly | Jindal Clinics by Dr. S.K Jindal
Medico-Legal Issues | Jindal Chest Clinic
Optimizing Management of asthma and COPD.ppt
Role of Allergen Immunotherapy in Allergic Asthma | Jindal Chest Clinic Chand...
Non-Respiratory Functions of The Respiratory System | Jindal Chest Clinic
Short Acting Beta-2 Agonists (SABA) in Asthma | Jindal Chest Clinic Chandigarh
Presentation on "Allergy" | Jindal chest clinic

Recently uploaded (20)

PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
Uterus anatomy embryology, and clinical aspects
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPTX
Note on Abortion.pptx for the student note
PPTX
Neuropathic pain.ppt treatment managment
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
SKIN Anatomy and physiology and associated diseases
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
PPT
Management of Acute Kidney Injury at LAUTECH
PDF
Khadir.pdf Acacia catechu drug Ayurvedic medicine
PDF
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPT
ASRH Presentation for students and teachers 2770633.ppt
PPTX
post stroke aphasia rehabilitation physician
PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PDF
Deadly Stampede at Yaounde’s Olembe Stadium Forensic.pdf
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
Medical Evidence in the Criminal Justice Delivery System in.pdf
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Uterus anatomy embryology, and clinical aspects
CT Anatomy for Radiotherapy.pdf eryuioooop
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
Note on Abortion.pptx for the student note
Neuropathic pain.ppt treatment managment
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
SKIN Anatomy and physiology and associated diseases
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
Management of Acute Kidney Injury at LAUTECH
Khadir.pdf Acacia catechu drug Ayurvedic medicine
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
Imaging of parasitic D. Case Discussions.pptx
ASRH Presentation for students and teachers 2770633.ppt
post stroke aphasia rehabilitation physician
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
Deadly Stampede at Yaounde’s Olembe Stadium Forensic.pdf
MENTAL HEALTH - NOTES.ppt for nursing students

Home nebulisation

  • 1. Home nebulisation Dr. Aditya Jindal Interventional Pulmonologist & Intensivist Jindal Clinics SCO 21, Sec 20D, Chandigarh DM Pulmonary and Critical Care Medicine (PGI Chandigarh), FCCP
  • 2. The respiratory tract has evolved to keep inhaled particles out of the lungs, and to remove or inactivate them once deposited ...
  • 3. The adult lung with dimensions and generations of the airways with predicted aerosol deposition Roy pleasants et al. Respiratory care. 2018
  • 4. Newman S P.Ther. Deliv. (2017)
  • 5. Factors influencing optimal delivery of inhaled drugs Droplet size Impaction Diffusion Sedimentation Pattern of inhalation Speed Cognition, disease severity, and clinical status of patient Roy pleasants et al. Respiratory care. 2018 Particles <5 µm  peripheral airways Particle > 5 µm  central airways
  • 6. Newman S P.Ther. Deliv. (2017)
  • 8. • Widespread hand-held inhalers’ devices are represented by • Dry powder inhalers (DPIs) • Pressurized metered dose inhalers (pMDIs) • Soft mist inhalers (SMIs) • Nebulizers are often left for the treatment of acute conditions such as COPD exacerbations or in patients with extremely limited self-sufficiency. Inhaler devices?? Dolovich MB, Ahrens RC, Hess DR, et al. Chest. 2005;127(1):335–371.
  • 9. Advantages and disadvantages of different types of inhaler devices in asthma and COPD Inhaler Formulation Metering system Pros Cons pMDI Drug suspended or dissolved in propellant (With surfactant or cosolvent) Metering valve and reservoir Compact and portable. Can be used independently. Dose counters Slow inhalation can be achieved Not breath actuated Not good for elderly Cold Freon effect Coordination issues Adding spacer makes it cumbersome and costly MDI with spacer Drug suspended or dissolved in propellant (With surfactant or cosolvent) Metering valve and reservoir Easy to coordinate Decreases oropharyngeal deposition Eliminates Cold Freon effect DPI Drug blend in lactose or drug alone/drug excipient particles/multidose blister reservoirs Capsules/blisters/ Compact and portable Do not require coordination Doesn’t contain propellants Requires minimum inspiratory flow Cant be used in emergencies Difficult in patients with cognitive impairment and elderly Most are moisture sensitive SMI Aqueous solution or suspension Unit dose blisters or reservoirs Compact and portable Doesn’t contain propellants Smaller dose of bronchodilator is required Metered volume of 15 mcl limits the dose deliver capacity Paola Rogliani et al. Respiratory Medicine 124 (2017) 6e14
  • 10. Device errors in asthma and COPD: Meta analysis • Studies in adult males and females with asthma or COPD, reporting at least one overall or critical error, using metered dose inhalers and dry powder inhalers were included. • Random-effect metaanalyses were performed to estimate device error rates and to compare pairs of devices. H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
  • 11. Meta-analysis of the overall error rate frequency for pMDI in prospective/cross-sectional studies Summary results for the MDI devices estimated an overall error frequency of 86.8% [95% CI 79.4–91.9] of patients with at least one error H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
  • 12. Meta-analysis of the overall error rate frequency (a) for DPIs in prospective/cross-sectional studies H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
  • 13. Device errors in asthma and COPD: Metaanalysis H.Chrstyn et al.npj Primary Care Respiratory Medicine (2017) 27:22
  • 14. 14 Factors Influencing Device Prescription Cleve Clin J Med. 2018 Feb;85(2 Suppl 1):S19-S27 J Assoc Physicians India. 2017 May;65(5):60-73 Chronic Obstr Pulm Dis. 2018; 5(2): 111–123. 1. Cognition 2. Manual dexterity 3. Comorbidities 4. Preference and outlook 5. Age 6. Poor eyesight Patient related 1.Type of drugs 2. Combination 3. Frequency of dosing 4. Strength of dose 5. Side effects 6. Large doses (if required) Drug related 1. Severity of disease 2. Respiratory status- lung condition Disease related Device related 1.Ease of use 2. Device efficacy 3. Cost 4. Duration of use
  • 15. Selecting Inhalation Device should be Based on Quality Of Actuation-inhalation Coordination & PIFR ERS Annual Congress London 2016 15 It is also recommended that patient preferences for devices should be considered when prescribing an inhaler, but physicians must be cognizant that patients often overestimate their ability to handle a device correctly
  • 16. 16 Ann Am Thorac Soc. 2017 Aug;14(8):1305-1311 1. sPIF is common during AECOPD and predicts all-cause and COPD readmission. Patients with sPIF may benefit therapies. 2. We recommend checking PIF in patients hospitalized for AECOPD for selection of delivery devices 1. Suboptimal PIFR (<60 L/min) has been observed in 19%-78% of stable outpatients and 32%–52% of inpatients before discharge from the hospital after treatment for COPD exacerbation 2. Patients with COPD and sPIFR had more severe dyspnea than patients with similar obstruction and optimal PIFR https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1132
  • 17. 17 Benefit of nebulization in patients with sub-optimal PIFR Ann Am Thorac Soc. 2017;14:1305–1311; J COPD Found. 2017;4:217–224. • Patients with suboptimal PIFR (<60L/min) discharged with nebulizers had significantly lower rates of COPD readmission as compared with those discharged on DPIs. Hospital Readmission 70 50 17 10 20 30 40 50 60 70 80 90 100 % of COPD-readmission < 90 D % of COPD-readmission < 30 D Nebulizer DPI (N=12) (N=10) P<0.005 P<0.011
  • 18. • Drug delivery via nebulization: • An effective alternative • An optimal dose can be delivered during tidal breathing. • Can be used with diferent disease severity or associated comorbidities, • Overcomes the need for coordination, specific handling and inspiratory maneuvers Nebulized devices?? Pierachille Santus, Dejan Radovanovic, Andrea Cristiano et al.2017:11 3257–3271
  • 19. Types of Nebulizers Alok G.Ghosal et al. Journal of The Association of Physicians of India.2017;65:60-73
  • 20. L. Vecellio. Breathe Mar 2006 Jet nebuliser
  • 21. L. Vecellio. Breathe Mar 2006 Ultrasonic nebuliser
  • 22. L. Vecellio. Breathe Mar 2006 Mesh nebuliser
  • 23. Patient profile for Nebulization • Patients with severe disease and exacerbations • During exacerbations where higher doses are needed • Elderly patients>60 years • Patients with physical and cognitive limitations • Patient preference Eur Respir J 2001; 18: 228–242 Ann Transl Med 2019;7(18):487
  • 24. What guidelines say about nebulization?
  • 26. Algorithm to identify OAD patients for maintenance nebulization *Clinical improvement should be assessed as recommended by the respective treatment guidelines. #Device technique should be assessed as per the patient information literature provided with the device. +Unsatisfactory device technique is any deviation from the recommended device technique described in the patient information literature provided with the device Alok G.Ghosal et al. Journal of The Association of Physicians of India.2017;65:60-73 Indian consensus statement on maintenance nebulization
  • 27. Guidelines in snapshot Cassandra D. Benge and John Alan Barwise. Federal practitioner (2020),160-163
  • 28. Drugs available in India for maintenance Nebulization Ghoshal AG, Salvi S, Dhar R, et al. J Assoc Physicians India. 2017;65(5):60-73.
  • 29. Nebulization in COVID 19 pandemic
  • 30. COVID 19 transmission • Spread by droplets generated as bioaerosols. • Aerosol transmission of SARS-CoV-2 is now considered to be the main method of transmission because the virus can remain viable and infectious in aerosols for hours Ari A. Respir Med. 2020;167:105987.
  • 31. Fugitive emissions during nebulization Fugitive emission is defined as aerosols that have been released from the aerosol device during patient expiration. It is also medical aerosols that are not inhaled by the patient but passes into the atmosphere. Previous studies: the particle size ranges from 0.860 to 1.437 μm Up to 50% of the generated aerosol during therapy was fugitive aerosol remain airborne in the indoor environment for several hours . Factors affecting fugitive emissions: The device, interface, patient type, and flow rate of nebulizer, dimensions and layout of the room, air turbulence, airflow rates, and temperature impact dispersion and decay Ari A. Respir Med. 2020;167:105987.
  • 33. Advise patients to have their full supply of medication at home1 Perform nebulization in a well ventilated room Prevent your caretaker/family member from staying inside the room during nebulization DON’T let the caretaker get too close while Nebulization is being conducted. Maintain distance of at least 6 feet from the patient. Close the door while nebulization is being undertaken.2 DON’T share nebulizers between family members. Every nebulizer should be a single-use nebulizer2. Avoid air-conditioning in the room altogether5. DO leave the room vacant with the door closed for 30 minutes after the patient has vacated the room post- nebulization.4 Wash the accessories as per the guide and use disinfectants like Isopropanol (70%) or Hydrogen Peroxide (3%) 4. 1WHO Interim guidelines 2019; 2CDC guidelines www.health.state.mn.us; 3https://www.cdc.gov/coronavirus/2019-ncov/hcp/hand-hygiene.html; 4https://www.health.qld.gov.au/data/assets/pdf_file/0038/939656/qh-covid-19-Infection-control-guidelines.pdf; 5www.ncdc.gov Good Nebulization Practice at HOME Setting
  • 34. Advantages of Nebulization J Assoc Physicians India. 2017 May;65(5):60-73; Nurse Prescribing. 2016 Dec 2;14(12):586-92 Med Devices (Auckl). 2015 Feb 12;8:131-9; Clinical Pediatrics;Vol. 47 No. 8; 2008 1. No patient coordination required. 2. Efficient delivery possible in patients with low inspiratory flow rate 3. Breath holding not required 4. Large doses can be administered
  • 35. • Issues with nebulisation • Droplet size formed is not uniform; may vary over 10 fold • Dose delivery depends on • Initial volume fill • Efficiency of aerosolisation of medicine • Amount residual/dead volume (0.5 – 1.5 ml) • Breath actuation vs continuous use
  • 36. Newman S P.Ther. Deliv. (2017)
  • 37. Alhaddad B et al. BMJ Open Resp Res 2015
  • 38. Alhaddad B et al. BMJ Open Resp Res 2015
  • 39. Cochrane Review: Nebulizers vs pMDI vs DPI • There is a lack of evidence in favour of one mode of delivery over another for bronchodilators during exacerbations of COPD. • No difference between nebulisers versus pMDI plus spacer regarding the primary outcomes of FEV1 at one hour and safety. • Secondary outcome: Change in FEV1 closest to one hour after dosing' during an exacerbation of COPD, a greater improvement in FEV1 when treating with nebulisers than with pMDI plus spacers. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD011826.
  • 40. Summary • Inhalation therapy is the preferred route of drug administration for treating COPD. • In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. • However, home nebulisation has its own problems and issues • If nebulized medications need to be used in patients with COVID-19 adequate precautions should be taken

Editor's Notes

  • #15: Current guidelines recommend that device selection should be made in consultation with the patient, who must be trained in inhaler device technique. https://www.guidelines.co.uk/respiratory/inhaler-choice-guideline/252870.article